|
|||||
|
|
Managing atopic dermatitis with systemic therapies in adults and adolescents: An Australian/New Zealand narrative |
|
| Authors: | Marius Rademaker Karen Agnew Megan Andrews Christopher Baker Peter Foley Kurt Gebauer Monisha Gupta Diana M. Rubel Colin Somerville John Sullivan Li-Chuen Wong |
| Affiliation: | 1. Waikato Clinical Campus, University of Auckland's Faculty of Medical and Health Sciences, Hamilton, New Zealand;2. Dermatology Department, Greenlane Clinical Centre, Auckland, New Zealand Starship Children's Hospital, Auckland, New Zealand;3. Woolloongabba, Queensland, Australia;4. St Vincent's Hospital, The University of Melbourne, Melbourne, Victoria, Australia Skin & Cancer Foundation Inc., Carlton, Victoria, Australia;5. University of Western Australia, Perth, Western Australia, Australia Probity Medical Research, Freemantle, Western Australia, Australia;6. Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia The Skin Hospital, Darlinghurst, New South Wales, Australia University of New South Wales, Sydney, New South Wales, Australia;7. Woden Dermatology, Phillip, Australian Capital Territory, Australia Australian National University, Canberra, Australian Capital Territory, Australia;8. The Allergy West Clinic - Immunology, Perth, Western Australia, Australia;9. Kingsway Dermatology, Miranda, New South Wales, Australia;10. The Children's Hospital at Westmead, Sydney, New South Wales, Australia |
| Abstract: | With the rapid development of new, targeted therapies for the treatment of moderate/severe atopic dermatitis, it is opportune to review the available conventional systemic agents. We assess the published evidence for systemic therapies for atopic dermatitis and amalgamate this with real-world experience. Discussions are centred on when systemic therapy should be considered, which drug(s), what dose, how to sequence or combine these therapies, how long they should be continued for and what is considered success. |
| Keywords: | atopic dermatitis atopic eczema azathioprine biologic therapies ciclosporin corticosteroids methotrexate mycophenolate second-line therapy small molecules systemic treatment |